pentylenetetrazole has been researched along with Convulsive Generalized Seizure Disorder in 38 studies
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.
pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA)." | 7.76 | Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats. ( Arcieri, S; Coppola, G; D'Aniello, A; Messana, T; Pascotto, A; Signoriello, G; Verrotti, A, 2010) |
| "This paper comprises a series of experiments in rodent models of partial and generalized epilepsy which were designed to describe the anti-convulsant profile of the functionalized amino acid lacosamide." | 7.74 | Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. ( Choi, D; Harris, RH; Kohn, H; Kupferberg, HJ; Stables, JP; Stöhr, T; Walton, N; White, HS, 2007) |
| "The incidence of seizures, their expression pattern and their latencies were registered and the severity was expressed by means of a five-point scale." | 5.39 | Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. ( Bialer, M; Hen, N; Kubová, H; Mareš, P; Yagen, B, 2013) |
| "The incidence of minimal, predominantly clonic seizures was not changed in any age group, but their latencies were prolonged in 18- and 25-day-old rats." | 5.31 | Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats? ( Haugvicová, R; Kubová, H; Mares, P, 2002) |
| " MET test (PTZ at the dose of 70 mg/kg) acute seizures in Wistar rats, in comparison to valproic acid (VPA)." | 3.76 | Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats. ( Arcieri, S; Coppola, G; D'Aniello, A; Messana, T; Pascotto, A; Signoriello, G; Verrotti, A, 2010) |
| " Dumont (Polygalaceae) were evaluated for anticonvulsant activity against tonic seizures produced in mice by pentylenetetrazole (PTZ), bicuculline, picrotoxin, and N-methyl-DL-aspartic acid (NMDLA)." | 3.74 | Anticonvulsant activity of Nylandtia spinosa L. Dumont (Polygalaceae) aqueous and methanol leaf extracts in mice. ( Amabeoku, G, 2008) |
| "This paper comprises a series of experiments in rodent models of partial and generalized epilepsy which were designed to describe the anti-convulsant profile of the functionalized amino acid lacosamide." | 3.74 | Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. ( Choi, D; Harris, RH; Kohn, H; Kupferberg, HJ; Stables, JP; Stöhr, T; Walton, N; White, HS, 2007) |
| "), status epilepticus (SE) of limbic seizures produced by kainic acid (KA, 10 mg/kg, i." | 3.73 | 5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats. ( González-Trujano, ME; Hong, E; López-Meraz, ML; Neri-Bazán, L; Rocha, LL, 2005) |
| "Experiments on male Wistar rats and Icr:Icl mice studied the influence of the novel compound--amino acid-containing 1,4-dihydropyridine derivative glutapyrone (G) on acute generalized seizures, arecoline and nicotine tremor, and 45Ca2+ uptake in brain synaptosomes." | 3.68 | [The anticonvulsant properties of glutapyrone--a new type of derivative of amino acid-containing 1,4-dihydropyridines]. ( Bisenieks, EA; Cebers, G; Duburs, GIa; Germane, SK; Karpova, MN; Klusa, VE; Pankov, OIu, 1993) |
| "Malondialdehyde (MDA) levels were significantly increased in the quercetin groups compared to the PTZ group in the hippocampus and cerebral cortex following PTZ kindling." | 1.39 | Effects of quercetin on oxidative stress and memory retrieval in kindled rats. ( Abbasi, E; Bazahang, P; Haghighi, MR; Lotfizadeh, M; Moghbelinejad, S; Nassiri-Asl, M; Yonesi, F, 2013) |
| "The incidence of seizures, their expression pattern and their latencies were registered and the severity was expressed by means of a five-point scale." | 1.39 | Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. ( Bialer, M; Hen, N; Kubová, H; Mareš, P; Yagen, B, 2013) |
| " Chronic administration of a subconvulsive dose of PTZ resulted in an increase in convulsive activity culminating in generalized clonic-tonic seizures, as revealed by a progressive increase in seizure score as well as alteration in antioxidant enzyme levels (lipid peroxidation, nitrite, glutathione, super oxide dismutase, and catalase) and mitochondrial complex (I, II, and IV) activities, whereas chronic treatment with hesperidin (200 mg/kg) significantly attenuated these behavioral, biochemical, and mitochondrial alterations." | 1.39 | Possible nitric oxide mechanism in the protective effect of hesperidin against pentylenetetrazole (PTZ)-induced kindling and associated cognitive dysfunction in mice. ( Kumar, A; Lalitha, S; Mishra, J, 2013) |
| "Valproic acid (VPA) is a major antiepileptic drug (AED) with efficacy against multiple seizure types." | 1.35 | Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases? ( Czapp, M; Hoffmann, K; Löscher, W, 2008) |
| "Memantine suppressed generalized tonic-clonic seizures in all age groups; minimal seizures were potentiated." | 1.35 | Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. ( Mares, P; Mikulecká, A, 2009) |
| "Thus, concerning the seizure modulating properties of both classes of receptors this study investigated whether the ultra-low dose opioid antagonist naltrexone influences cannabinoid anticonvulsant effects." | 1.35 | The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. ( Bahremand, A; Dehpour, AR; Ghasemi, M; Gholizadeh, S; Nasrabady, SE; Shafaroodi, H, 2008) |
| "The incidence of minimal, predominantly clonic seizures was not changed in any age group, but their latencies were prolonged in 18- and 25-day-old rats." | 1.31 | Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats? ( Haugvicová, R; Kubová, H; Mares, P, 2002) |
| " GTCSs were suppressed by TGB in the adult and 25-day-old rats, and a U-shaped dose-response curve was outlined in these two groups." | 1.31 | Two different anticonvulsant actions of tiagabine in developing rats. ( Haugvicová, R; Kubová, H; Mares, P; Skutová, M; Suchomelová, L, 2000) |
| " Both effects exhibited a tendency to a U-shaped dose-response curve." | 1.30 | Anticonvulsant action of gabapentin during postnatal development in rats. ( Haugvicová, R; Mares, P, 1997) |
| "In conclusion, the results confirm a genetic susceptibility in GAERS and/or resistance in inbred non-epileptic rats to focal and generalized seizures involving the cortex." | 1.30 | Susceptibility to focal and generalized seizures in Wistar rats with genetic absence-like epilepsy. ( Boehrer, A; Brailowsky, S; Marescaux, C; Montiel, T; Vergnes, M, 1999) |
| "Minimal, predominantly clonic seizures with preserved righting ability were reliably induced by pentylenetetrazol and suppressed by clobazam in rats aged 18 days or more." | 1.30 | Antipentylenetetrazol action of clobazam in developing rats. ( Haugvicová, R; Kubová, H; Mares, P, 1999) |
| "In all experiments, the PTZ seizure threshold was repeatedly determined in individual rats with chronically implanted catheters at daily intervals." | 1.29 | Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats. ( Hönack, D; Löscher, W, 1995) |
| "One-third of migraine patients, mostly of young age, suffering from migraine with aura and basilar migraine had such consciousness disorders as stupefaction and syncopes." | 1.29 | [Migraine and epilepsy: clinical comparisons and the characteristics of the cerebral blood circulation]. ( Larikova, TI; Shestakov, VV, 1994) |
| "Although calcium antagonists possess antiepileptic properties in various models of epilepsy, their role after chronic administration and in models for generalized absence epilepsy has not been studied." | 1.29 | The effects of chronic treatment with a calcium channel antagonist on two types of generalized epilepsies in rats. ( Ates, N; van der Staay, FJ; van Luijtelaar, EL, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (36.84) | 18.2507 |
| 2000's | 18 (47.37) | 29.6817 |
| 2010's | 6 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nassiri-Asl, M | 1 |
| Moghbelinejad, S | 1 |
| Abbasi, E | 1 |
| Yonesi, F | 1 |
| Haghighi, MR | 1 |
| Lotfizadeh, M | 1 |
| Bazahang, P | 1 |
| Mareš, P | 9 |
| Kubová, H | 5 |
| Hen, N | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Kumar, A | 1 |
| Lalitha, S | 1 |
| Mishra, J | 1 |
| Snehunsu, A | 1 |
| Ghosal, C | 1 |
| Kandwal, M | 1 |
| Yadav, PK | 1 |
| Nayak, BS | 1 |
| Rao, KR | 1 |
| Kamath, SU | 1 |
| Sahoo, P | 1 |
| Srinivasan, KK | 1 |
| Naduvil Narayanan, S | 1 |
| Kumar, S | 1 |
| Joseph, A | 1 |
| Hoffmann, K | 1 |
| Czapp, M | 1 |
| Löscher, W | 3 |
| Mikulecká, A | 2 |
| Amabeoku, G | 1 |
| Coppola, G | 1 |
| Arcieri, S | 1 |
| D'Aniello, A | 1 |
| Messana, T | 1 |
| Verrotti, A | 1 |
| Signoriello, G | 1 |
| Pascotto, A | 1 |
| Medeiros, Dde C | 1 |
| Cota, VR | 1 |
| Vilela, MR | 1 |
| Mourão, FA | 1 |
| Massensini, AR | 1 |
| Moraes, MF | 1 |
| Haugvicová, R | 6 |
| Meilleur, S | 1 |
| Aznavour, N | 1 |
| Descarries, L | 1 |
| Carmant, L | 1 |
| Mamer, OA | 1 |
| Psarropoulou, C | 1 |
| Nekrassov, V | 1 |
| Sitges, M | 1 |
| Krahl, SE | 1 |
| Senanayake, SS | 1 |
| Handforth, A | 1 |
| López-Meraz, ML | 1 |
| González-Trujano, ME | 1 |
| Neri-Bazán, L | 1 |
| Hong, E | 1 |
| Rocha, LL | 1 |
| Kasal, A | 1 |
| Stöhr, T | 1 |
| Kupferberg, HJ | 1 |
| Stables, JP | 1 |
| Choi, D | 1 |
| Harris, RH | 1 |
| Kohn, H | 1 |
| Walton, N | 1 |
| White, HS | 1 |
| Marcus, EM | 1 |
| Jacobson, S | 1 |
| Bahremand, A | 1 |
| Shafaroodi, H | 1 |
| Ghasemi, M | 1 |
| Nasrabady, SE | 1 |
| Gholizadeh, S | 1 |
| Dehpour, AR | 1 |
| Hönack, D | 2 |
| Shestakov, VV | 1 |
| Larikova, TI | 1 |
| van Luijtelaar, EL | 1 |
| Ates, N | 1 |
| van der Staay, FJ | 1 |
| Seiler, N | 1 |
| Sarhan, S | 1 |
| Knoedgen, B | 1 |
| Hornsperger, JM | 1 |
| Sablone, M | 1 |
| Karpova, MN | 3 |
| Germane, SK | 2 |
| Cebers, G | 1 |
| Pankov, OIu | 3 |
| Klusa, VE | 1 |
| Duburs, GIa | 1 |
| Bisenieks, EA | 1 |
| Klusha, VE | 1 |
| Duburs, G | 1 |
| Brailowsky, S | 1 |
| Montiel, T | 1 |
| Boehrer, A | 1 |
| Marescaux, C | 1 |
| Vergnes, M | 1 |
| Watanabe, T | 1 |
| Morimoto, K | 1 |
| Hirao, T | 1 |
| Suwaki, H | 1 |
| Watase, K | 1 |
| Tanaka, K | 1 |
| Silveira, DC | 1 |
| Holmes, GL | 1 |
| Schachter, SC | 1 |
| Geula, C | 1 |
| Schomer, DL | 1 |
| Skutová, M | 2 |
| Suchomelová, L | 1 |
| Keskil, IS | 1 |
| Keskil, ZA | 1 |
| Canseven, AG | 1 |
| Seyhan, N | 1 |
| Raza, M | 1 |
| Shaheen, F | 1 |
| Choudhary, MI | 1 |
| Suria, A | 1 |
| Rahman, AU | 1 |
| Sombati, S | 1 |
| DeLorenzo, RJ | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Abramova, EM | 1 |
| Abrosimov, IIu | 1 |
| Daval, JL | 1 |
| Pereira de Vasconcelos, A | 1 |
| el Hamdi, G | 1 |
| Werck, MC | 1 |
| Nehlig, A | 1 |
| Fischer, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Effects of Levetiracetam on Cortical Excitability in Humans[NCT00006191] | 14 participants | Observational | 2000-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
38 other studies available for pentylenetetrazole and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Effects of quercetin on oxidative stress and memory retrieval in kindled rats.
Topics: Animals; Antioxidants; Avoidance Learning; Brain; Convulsants; Disease Models, Animal; Dithionitrobe | 2013 |
Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats.
Topics: Aging; Allylisopropylacetamide; Amides; Animals; Anticonvulsants; Convulsants; Epilepsy, Generalized | 2013 |
Possible nitric oxide mechanism in the protective effect of hesperidin against pentylenetetrazole (PTZ)-induced kindling and associated cognitive dysfunction in mice.
Topics: Animals; Avoidance Learning; Brain; Cognition Disorders; Convulsants; Disease Models, Animal; Dose-R | 2013 |
1-Triacontanol cerotate; isolated from Marsilea quadrifolia Linn. ameliorates reactive oxidative damage in the frontal cortex and hippocampus of chronic epileptic rats.
Topics: Animals; Chronic Disease; Dose-Response Relationship, Drug; Epilepsy, Generalized; Fatty Alcohols; F | 2015 |
Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy, Genera | 2008 |
Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Convulsants; Dose-Response Relationship, Drug; Epilepsy, | 2009 |
Anticonvulsant activity of Nylandtia spinosa L. Dumont (Polygalaceae) aqueous and methanol leaf extracts in mice.
Topics: Animals; Anticonvulsants; Bicuculline; Convulsants; Epilepsy, Generalized; Lethal Dose 50; Male; Met | 2008 |
Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats.
Topics: Animals; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Electroshock; Epilepsy, Gen | 2010 |
Anatomically dependent anticonvulsant properties of temporally-coded electrical stimulation.
Topics: Amygdala; Animals; Disease Models, Animal; Electric Stimulation Therapy; Epilepsy, Generalized; Male | 2012 |
Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats?
Topics: Animals; Animals, Newborn; Anticonvulsants; Convulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clon | 2002 |
Pentylenetetrazol-induced seizures in immature rats provoke long-term changes in adult hippocampal cholinergic excitability.
Topics: Acetylcholine; Age Factors; Animals; Animals, Newborn; Cholinergic Fibers; Cholinesterase Inhibitors | 2003 |
Effects of pentylenetetrazole and 4-aminopyridine on the auditory brainstem response (ABR) and on the hearing sensitivity in the guinea pig in vivo.
Topics: 4-Aminopyridine; Animals; Auditory Threshold; Convulsants; Electroencephalography; Epilepsy, General | 2003 |
Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided.
Topics: Animals; Disease Models, Animal; Electric Stimulation Therapy; Electrodes; Epilepsy, Generalized; Fu | 2003 |
MPEP, an antagonist of metabotropic glutamate receptors, exhibits anticonvulsant action in immature rats without a serious impairment of motor performance.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Ep | 2004 |
5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats.
Topics: 5-Methoxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Anticonvulsants; Con | 2005 |
Action of two neuroactive steroids against motor seizures induced by pentetrazol in rats during ontogeny.
Topics: Age Factors; Anesthetics; Animals; Animals, Newborn; Convulsants; Desoxycorticosterone; Epilepsy, Ge | 2006 |
Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy.
Topics: Acetamides; Animals; Anticonvulsants; Bicuculline; Cobalt; Convulsants; Electroshock; Epilepsies, Pa | 2007 |
Historical perspective on PTZ-induced seizures.
Topics: Animals; Cats; Dose-Response Relationship, Drug; Epilepsy, Generalized; History, 20th Century; Human | 2007 |
The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoids; Convulsant | 2008 |
Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats.
Topics: Animals; Delayed-Action Preparations; Epilepsy, Generalized; Female; Infusions, Intravenous; Pentyle | 1995 |
[Migraine and epilepsy: clinical comparisons and the characteristics of the cerebral blood circulation].
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Electroencephalography; Epilepsies, Partial; Epile | 1994 |
The effects of chronic treatment with a calcium channel antagonist on two types of generalized epilepsies in rats.
Topics: Animals; Calcium Channel Blockers; Diet; Electroencephalography; Epilepsy, Absence; Epilepsy, Genera | 1994 |
Enhanced endogenous ornithine concentrations protect against tonic seizures and coma in acute ammonia intoxication.
Topics: 3-Mercaptopropionic Acid; Ammonia; Animals; Brain Chemistry; Coma; Dialysis; Dizocilpine Maleate; El | 1993 |
[The anticonvulsant properties of glutapyrone--a new type of derivative of amino acid-containing 1,4-dihydropyridines].
Topics: Animals; Anticonvulsants; Arecoline; Calcium; Cerebral Cortex; Dihydropyridines; Drug Evaluation, Pr | 1993 |
[The antiepileptic effects of the combined action of the new 1,4-dihydropyridine derivative glutapyrone with sodium valproate and phenobarbital].
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Dihydropyridines; Drug Evaluation, Preclinical; Drug Ther | 1993 |
Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Dose-Response Relationship, Drug; Electrodes; | 1993 |
Anticonvulsant action of gabapentin during postnatal development in rats.
Topics: Acetates; Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Cyclohexanecarboxylic Acids; Do | 1997 |
Susceptibility to focal and generalized seizures in Wistar rats with genetic absence-like epilepsy.
Topics: Animals; Convulsants; Electroencephalography; Epilepsies, Partial; Epilepsy, Absence; Epilepsy, Gene | 1999 |
Amygdala-kindled and pentylenetetrazole-induced seizures in glutamate transporter GLAST-deficient mice.
Topics: Amino Acid Transport System X-AG; Amygdala; Animals; Astrocytes; ATP-Binding Cassette Transporters; | 1999 |
Antipentylenetetrazol action of clobazam in developing rats.
Topics: Age Factors; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain; Clobazam; Convul | 1999 |
Increased susceptibility to generalized seizures after immunolesions of the basal forebrain cholinergic neurons in rats.
Topics: Acetylcholinesterase; Animals; Convulsants; Denervation; Disease Susceptibility; Epilepsy, Generaliz | 2000 |
Anticonvulsant action of topiramate against motor seizures in developing rats.
Topics: Age Factors; Animals; Anticonvulsants; Behavior, Animal; Brain; Disease Models, Animal; Epilepsy, Ge | 2000 |
Two different anticonvulsant actions of tiagabine in developing rats.
Topics: Age Factors; Animals; Animals, Newborn; Anticonvulsants; Brain; Disease Models, Animal; Dose-Respons | 2000 |
No effect of 50 Hz magnetic field observed in a pilot study on pentylenetetrazol-induced seizures and mortality in mice.
Topics: Animals; Convulsants; Electromagnetic Fields; Epilepsy, Generalized; Female; Mice; Pentylenetetrazol | 2001 |
Anticonvulsant activities of the FS-1 subfraction isolated from roots of Delphinium denudatum.
Topics: Animals; Anticonvulsants; Bicuculline; Dose-Response Relationship, Drug; Electroshock; Epilepsy, Gen | 2001 |
[The antiepileptic effects of sodium valproate and the calcium antagonist riodipine when used jointly in a model of generalized korazol-induced epileptic activity].
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Ev | 1992 |
Quantitative autoradiographic measurements of functional changes induced by generalized seizures in the developing rat brain: central adenosine and benzodiazepine receptors and local cerebral glucose utilization.
Topics: Age Factors; Animals; Autoradiography; Bicuculline; Blood Glucose; Brain; Brain Mapping; Epilepsy, G | 1992 |
[The anticonvulsant action of 5-hydroxy-L-tryptophan in various seizure models in the mouse].
Topics: 5-Hydroxytryptophan; Animals; Anticonvulsants; Electroshock; Epilepsy, Generalized; Epilepsy, Tonic- | 1991 |